Pacific Edge, the New Zealand-based diagnostics company, said Tuesday that its Asia-Pacific testing business is closing in on profitability, even as its US operations faced a setback from sales team attrition. The update, filed with the Australian and New Zealand stock exchanges, showed diverging trends across the company's two main markets.
APAC Volumes Surge, US Volumes Dip
In the first quarter of fiscal 2027, commercial test volumes in the Asia-Pacific region rose nearly 13% compared to the previous quarter, reaching 1,158 tests. The growth was driven by broader adoption of the company's Cxbladder Triage Plus test, a non-invasive urine test designed to help rule out bladder cancer in patients with blood in their urine.
In contrast, US test volumes fell 2.4% quarter-on-quarter, as the company worked through turnover in its US sales team. Pacific Edge did not disclose the exact number of departures, but noted that the attrition temporarily disrupted its ability to maintain momentum with healthcare providers.
The company's overall commercial test volumes—which include both APAC and US operations—rose modestly, but the regional split highlights the challenges of building a global diagnostics business.
Why Volume Growth Matters for a Lab Business
For diagnostics companies like Pacific Edge, test volume is a critical metric. Lab-based businesses have high fixed costs—laboratories, equipment, regulatory compliance, and skilled personnel—but relatively low variable costs per test. Once the infrastructure is in place, each additional test adds only a small incremental cost, meaning that higher volumes can quickly translate into better margins and a faster path to profitability.
Pacific Edge's APAC business is now approaching the breakeven point, according to the company. That would be a significant milestone for a firm that has invested heavily in building its testing network and commercial presence across the region. The company's Cxbladder tests are used by urologists and primary care physicians to reduce the need for invasive cystoscopies, and the technology has gained traction in markets like Australia and New Zealand.
The broader economic backdrop in New Zealand has been mixed. While business confidence has rebounded recently, as noted in a separate report on New Zealand Business Confidence Rebounds as Fuel Costs Ease, but RBNZ Tightening Continues, the Reserve Bank of New Zealand has kept interest rates elevated to combat inflation. That tightening cycle can affect healthcare spending and hospital budgets, making cost-effective diagnostic tools like Cxbladder more attractive to health systems.
What It Means for Investors
For everyday investors, Pacific Edge's update offers a window into the operational realities of a small-cap diagnostics company. The divergence between APAC and US performance underscores the importance of geographic diversification—and the risks of relying on a single sales team in a competitive market like the US.
The US volume dip is a reminder that sales force turnover can have an immediate impact on revenue, even if the underlying product is strong. Pacific Edge will need to stabilize its US sales team and rebuild momentum to avoid further erosion. Investors should watch for updates on hiring and training in the coming quarters.
On the positive side, the APAC growth suggests that the company's technology is finding a receptive audience outside the US. If the APAC business can reach profitability, it could provide a more stable financial base from which to invest in US expansion. The company's ability to manage costs while scaling volumes will be key.
Pacific Edge's stock is listed on both the Australian Securities Exchange (ASX) and the New Zealand Stock Exchange (NZX), making it accessible to investors in those markets. The company does not trade on major US exchanges, but US investors can access it through certain brokers that offer international trading.
Looking ahead, the company's next quarterly update will be closely watched for signs of US recovery and further APAC progress. Investors should also keep an eye on broader trends in bladder cancer diagnostics and reimbursement policies, which can affect adoption rates.
For context, other companies in the diagnostics space have faced similar challenges. For example, TCS Restructures US Operations and Launches New Business Units Amid AI Shift highlights how even large firms must adapt their sales structures to changing market conditions. Meanwhile, the broader dealmaking environment has been active, with Big Banks Set for Best Dealmaking Quarter Since 2021 as Fees Surge, though Pacific Edge is not directly involved in M&A.
Ultimately, Pacific Edge's path to profitability hinges on its ability to grow volumes in both regions while controlling costs. The APAC progress is encouraging, but the US setback shows that execution remains a challenge.
